OBJECTIVES: Assess feasibility of instituting a PBM program engaging pharmacists as prescriber-extenders for care of patients with type 2 diabetes mellitus (T2DM). METHODS: Surveys included 146 payors (15 questions) and 2000 T2DM prescribers (Internal Medicine [IM], Endocrinologists/Diabetes specialists [ENDO/DS] and Family practitioners [FP]; (30 questions). After a description of a pharmacist-managed basal insulin initiation/intensification program, the survey evaluated interest and importance of program components including: adherence reports, format/content/frequency of reports, drug spend, care/management of T2DM, access to care, patient education/counseling, pharmacist training, and additional management tools.  Statistical comparisons were done by chi-square or Wilcoxon test analysis. RESULTS: Payor response rate was 13%. They included large (approx 1M), young (age 35±4) membership in the Northeast. They believe prescribers will be interested in receiving T2DM medication adherence reports (100%) and participating in the program (68%).  Importance was assigned to increased access of care (95%) and management of patients (100%), but less-so on pharmacist training (53%). The prescriber response rate was 7%: 70% ENDO/DS and 29% IM/FP. Compared to ENDO/DS, more IM/FP believe the program would improve overall care (64% vs 38%), increase patient education/counseling (57% vs 33%), and wanted T2DM medication adherence reports (76% vs 40%) [all p<0.05]. More IM/FP (43%) than ENDO/DS (19%, p<0.05) state they would refer patients to the program.  For most prescribers, financial compensation was not a driving factor, while contact of pharmacist/patient contact/dialog was important. Approximately 60% of IM/FP and 40% of ENDO/DS were willing to share blood pressure, lipid, and hemoglobin A1C values with pharmacists. CONCLUSIONS: Payors are interested in improving care and management of T2DM and endorse a PBM-based pharmacist physician-extender program. Primary care prescribers were more supportive of the program, willing to share data, and likely to refer patients than Endocrinologists/Diabetes specialists. Considering response bias, overall, the program is feasible and has been implemented.